Immutep Ltd has released a press release.
Appendix 4E & 2018 Full Year Statutory Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- TACTI-mel Patient Recruitment Complete & Operational Update
- Immutep receives IND approval from US FDA for IMP321
- Immutep submits IND application with FDA
- Mid-point of patient enrolment reached in AIPAC trial
- Webcast slides for TACTI-mel clinical trial data
Later from Immutep
- Progress towards clinical development of IMP761
- Immutep enters into collaboration with Pfizer & Merck KGaA
- Positive interim TACTI-mel data presented at SITC
- Immutep granted European patent for IMP321
- European patent granted for IMP321 & antibody combinations
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep